NCT05028361View on ClinicalTrials.gov

Simultaneous mRNA COVID-19 and IIV4 Vaccination Study

PHASE4CompletedINTERVENTIONAL
Enrollment

348

Participants

Timeline

Start Date

October 4, 2021

Primary Completion Date

March 3, 2023

Study Completion Date

June 15, 2023

Conditions
Quality of LifeInjection Site ReactionAdverse Drug EventSystemic Reaction
Interventions
BIOLOGICAL

mRNA COVID-19

ACIP-CDC recommended vaccine

BIOLOGICAL

IIV4

ACIP recommended vaccine

OTHER

Placebo (saline)

Saline Control

Trial Locations (3)

21205

John Hopkins University, Baltimore

27709

Duke University, Durham

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
collaborator

Centers for Disease Control and Prevention

FED

collaborator

Johns Hopkins University

OTHER

collaborator

Children's Hospital Medical Center, Cincinnati

OTHER

lead

Duke University

OTHER